Skip to main content
Quest Diagnostics

Comment on ‘Predictive Factors for Eczematous Eruptions and Candidiasis During Anti-Interleukin-17 Treatment in Patients With Psoriasis’: Bimekizumab-Induced Spongiotic Dermatitis

Comment on ‘Predictive Factors for Eczematous Eruptions and Candidiasis During Anti-Interleukin-17 Treatment in Patients With Psoriasis’: Bimekizumab-Induced Spongiotic Dermatitis

Authors: Houff AN, Cohen J, Sami N

Citation: Clin Exp Dermatol. 2025 Nov 7:llaf425. doi: 10.1093/ced/llaf425. Online ahead of print.

Specialties: Dermatology, Immunology

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Test FAQ
Therapeutic Monoclonal Antibody Drug Monitoring
Publication
Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States
On-Demand Webinar
Autoimmune Disease and Cardiometabolic Risk

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.